• The U.S. Senate has passed a revised version of the Holding Foreign Companies Accountable Act (HFCAA), which gives U.S. firms more time to comply with the law's requirements. The original HFCAA required companies listed on U.S. exchanges to prove they are not controlled by a foreign government or face delisting. The revised bill extends the compliance timeline from three years to five years, providing more flexibility for U.S. firms to cut ties with Chinese biotechnology companies.

• The HFCAA was enacted in 2020 to address concerns about the ability of U.S. regulators to inspect the audits of companies listed on U.S. exchanges, particularly those based in China. The revised bill aims to give U.S. firms more time to navigate the complex regulatory environment and make necessary adjustments to their business relationships with Chinese biotechnology companies.

• The extended compliance timeline is expected to benefit U.S. firms that have significant investments or partnerships with Chinese biotechnology companies. This additional time will allow them to gradually disengage from these relationships and find alternative sources or partners, reducing the potential impact on their operations and financial performance.